• A
• A
• A

Herceptin® Improves Outcome of HER2-positive Stomach Cancer (09/25/2009)
According to the results of a Phase III clinical trial, treatment with the targeted therapy Herceptin® (trastuzumab) improves survival among patients with HER2-positive, advanced and inoperable stomach cancer. These results were presented at a major European cancer conference.

Aspirin May Reduce Risk of Stomach Cancer (08/28/2009)
Regular aspirin use may reduce the risk of distal stomach cancer (cancer in the lower part of the stomach). These results were published in the American Journal of Epidemiology.

Herceptin® Improves Survival with HER2-positive Gastric Cancer (06/02/2009)
According to the results of a Phase III clinical trial presented at the 2009 annual meeting of the American Society of Clinical Oncology (ASCO), treatment with a combination of chemotherapy and the targeted drug Herceptin® (trastuzumab) results in better survival than chemotherapy alone among patients with advanced, HER2-positive gastric (stomach) cancer.

Laparoscopic Surgery Results in Fewer Complications for Patients with Stomach Cancer (05/08/2009)
Laparoscopic surgery produces a similar rate of recurrence-free survival as traditional open surgery in patients with gastric cancer but results in fewer complications and shorter hospital stays, according to the results of a study published in the Annals of Surgical Oncology.

In Gastric Cancer Antibiotics Following Surgery Reduce Risk of Second Gastric Cancer (08/04/2008)
Among patients diagnosed with gastric (stomach) cancer, a combination of antibiotics against the bacterium Helicobacter pylori (H. pylori) significantly reduces the risk of developing a second gastric cancer. These results were recently published in the August 2008 issue of Lancet Oncology.

▪ More...

Herceptin® Improves Survival with HER2-positive Gastric Cancer (06/02/2009)
According to the results of a Phase III clinical trial presented at the 2009 annual meeting of the American Society of Clinical Oncology (ASCO), treatment with a combination of chemotherapy and the targeted drug Herceptin® (trastuzumab) results in better survival than chemotherapy alone among patients with advanced, HER2-positive gastric (stomach) cancer.

Increased Doses of Gleevec® for Gleevec-Resistant Gastrointestinal Stromal Tumors (GIST) Effective (08/17/2005)
According to a recent article published in the European Journal of Cancer, increasing doses of Gleevec® (imatinib) provides anti-cancer activity in patients diagnosed with Gastrointestinal Stromal Tumors (GIST) that had stopped responding to lower doses of the drug.  

Lab Test Shows Promise for Detecting Gastric Cancer Recurrence (02/08/2005)
A recent study in the American Journal of Clinical Oncology reports that a lab test analyzing a cancer marker known as carcinoembryonic antigen (CEA) may be useful in identifying patients who may be at risk for recurrence of gastric cancer.

Mortality from Some Cancer Surgeries Reduced in Large-Volume Hospitals (01/23/2003)
According to a recent article published in The New England Journal of Medicine, death related to surgical procedures (surgical mortality) for some cancers may be significantly reduced if patients receive treatment in hospitals that perform large volumes of the surgical procedure annually.

Postoperative Enteral Nutrition Reduces Complications in Gastrointestinal Cancer (02/12/2002)
According to results published in the Lancet, postoperative enteral nutrition may significantly reduce complications and the length of hospital stays for patients with gastrointestinal cancer.

Aspirin May Reduce Risk of Stomach Cancer (08/28/2009)
Regular aspirin use may reduce the risk of distal stomach cancer (cancer in the lower part of the stomach). These results were published in the American Journal of Epidemiology.

Fruits and Vegetables Reduce Risk of Stomach Cancer (02/01/2008)
According to an article recently published in the American Journal of Epidemiology, diets higher in vegetables and fruits and lower in foods common in Western diets (such as processed meats, soft drinks, and sugars) can significantly reduce the risk of developing stomach cancer.

Epstein-Barr Virus Not Associated with Gastric Cancer (11/29/2007)
According to an article recently published in the British Journal of Cancer, individuals infected with the Epstein-Barr virus (EBV) do not have an increased risk of gastric cancer.

Incidence of Precancerous Changes to the Stomach is Declining (08/21/2007)
According to the results of a study conducted in the Netherlands and published in the journal Gut, the frequency of precancerous changes to the stomach (atrophic gastritis, intestinal metaplasia, and dysplasia) is declining; this should result in a drop in stomach cancer rates in the future.

Airborne Exposure to Some Chemicals May Increase Stomach Cancer Risk (03/14/2007)
According to an article recently published in the International Journal of Cancer, airborne exposure to some occupational carcinogens appears to increase the risk of noncardia gastric cancer among men.

▪ More...

Laparoscopic Surgery Results in Fewer Complications for Patients with Stomach Cancer (05/08/2009)
Laparoscopic surgery produces a similar rate of recurrence-free survival as traditional open surgery in patients with gastric cancer but results in fewer complications and shorter hospital stays, according to the results of a study published in the Annals of Surgical Oncology.

In Gastric Cancer Antibiotics Following Surgery Reduce Risk of Second Gastric Cancer (08/04/2008)
Among patients diagnosed with gastric (stomach) cancer, a combination of antibiotics against the bacterium Helicobacter pylori (H. pylori) significantly reduces the risk of developing a second gastric cancer. These results were recently published in the August 2008 issue of Lancet Oncology.

Removal of More Lymph Nodes May Improve Survival in Gastric and Pancreatic Cancers (07/23/2008)
Researchers recommend that at least 15 lymph nodes be removed and examined in patients with early gastric or pancreatic cancers. These results were recently published in the Archives of Surgery.

Combination of Chemotherapy and Immunotherapy Shows Promise for Gastric Cancer (03/24/2008)
A combination of chemotherapy and immunotherapy (chemoimmunotherapy) may improve overall survival among gastric cancer patients. These findings were recently published in the Annals of Oncology.

Identification of Cellular Enzymes May Predict Prognosis of Gastric Cancer (02/27/2008)
An important enzyme known as histone deacetylase may contain useful information about the prognosis of gastric cancer. These findings were recently published in the Lancet.

▪ More...

Herceptin® Improves Outcome of HER2-positive Stomach Cancer (09/25/2009)
According to the results of a Phase III clinical trial, treatment with the targeted therapy Herceptin® (trastuzumab) improves survival among patients with HER2-positive, advanced and inoperable stomach cancer. These results were presented at a major European cancer conference.

Herceptin® Improves Survival with HER2-positive Gastric Cancer (06/02/2009)
According to the results of a Phase III clinical trial presented at the 2009 annual meeting of the American Society of Clinical Oncology (ASCO), treatment with a combination of chemotherapy and the targeted drug Herceptin® (trastuzumab) results in better survival than chemotherapy alone among patients with advanced, HER2-positive gastric (stomach) cancer.

In Gastric Cancer Antibiotics Following Surgery Reduce Risk of Second Gastric Cancer (08/04/2008)
Among patients diagnosed with gastric (stomach) cancer, a combination of antibiotics against the bacterium Helicobacter pylori (H. pylori) significantly reduces the risk of developing a second gastric cancer. These results were recently published in the August 2008 issue of Lancet Oncology.

No Treatment Advantage with Cisplatin for Gastric Cancer (04/02/2008)
Results from a recent study indicate that the addition of the drug cisplatin (Platinol®) did not improve response rates, survival rates, or progression-free survival for patients with gatric cancer. These findings were published in The Annals of Oncology.

Combination Chemotherapy Has Potential as Standard Treatment for Advanced Gastric Cancer (03/03/2008)
A combination of S-1 and cisplatin chemotherapy may become the first-line therapy for patients with advanced gastric cancer. These findings were recently published in Lancet Oncology.

▪ More...